The biology of breast carcinoma

被引：137

作者：

Keen, JC ^{[1
]}

Davidson, NE ^{[1
]}

机构：

[1] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

来源：

CANCER | 2003年 / 97卷 / 03期

关键词：

D O I：

10.1002/cncr.11126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The biology of breast carcinoma is complex, with multiple factors contributing to its development and progression. The current review focuses on the role of several critical genes including estrogen receptor, progesterone receptor, retinoic acid receptor-beta, epidermal growth factor receptor family members, p53, BRCA1, and BRCA2 as risk factors for the development of disease, predictors of prognosis and response to therapy, and as therapeutic targets. Studies of the biology of these and other genes that contribute to the development and progression of breast carcinoma have had and will continue to have great impact on all aspects of disease management. (C) 2003 American Cancer Society.

引用

页码：825 / 833

页数：9

共 108 条

[81] Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk [J].

Rohan, TE ;

Hartwick, W ;

Miller, AB ;

Kandel, RA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17) :1262-1269

[82] Absence of estrogen receptor-β expression in metastatic ovarian cancer [J].

Rutherford, T ;

Brown, WD ;

Sapi, E ;

Aschkenazi, S ;

Muñoz, A ;

Mor, G .

OBSTETRICS AND GYNECOLOGY, 2000, 96 (03) :417-421

[83] Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide [J].

Sabichi, AL ;

Hendricks, DT ;

Bober, MA ;

Birrer, MJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08) :597-605

[84]

Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49

[85] Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer [J].

Siegel, PM ;

Ryan, ED ;

Cardiff, RD ;

Muller, WJ .

EMBO JOURNAL, 1999, 18 (08) :2149-2164

[86] Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells [J].

Sirchia, SM ;

Ferguson, AT ;

Sironi, E ;

Subramanyan, S ;

Orlandi, R ;

Sukumar, S ;

Sacchi, N .

ONCOGENE, 2000, 19 (12) :1556-1563

[87]

Sirchia SM, 2002, CANCER RES, V62, P2455

[88] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].

SLAMON, DJ ;

GODOLPHIN, W ;

JONES, LA ;

HOLT, JA ;

WONG, SG ;

KEITH, DE ;

LEVIN, WJ ;

STUART, SG ;

UDOVE, J ;

ULLRICH, A ;

PRESS, MF .

SCIENCE, 1989, 244 (4905) :707-712

[89] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[90] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

← 2 3 4 5 6 7 8 9 10 11 →